Ocumension Therapeutics (HKG:1477) obtained approval to carry out a real world study of OT-703 (ILUVIEN) in Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, China, a Tuesday Hong Kong bourse filing said.
OT-703 is an injectable, non-biodegradable fluocinolone acetate intravitreal implant for the treatment of diabetic macular edema.
In April 2021, the drugmaker had obtained exclusive licensed rights from Alimera Sciences for the development and commercialization of ILUVIEN in Greater China, South Korea and 11 countries in Southeast Asia.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。